Vinner Gurinder K, Malik Danish J
Chemical Engineering Department, Loughborough University, Loughborough, LE11 3TU, United Kingdom.
Chemical Engineering Department, Loughborough University, Loughborough, LE11 3TU, United Kingdom.
Res Microbiol. 2018 Nov;169(9):522-530. doi: 10.1016/j.resmic.2018.05.011. Epub 2018 Jun 7.
A Salmonella specific bacteriophage Felix O1 (Myoviridae) was microencapsulated in a pH responsive polymer formulation. The formulation incorporated a pH responsive methacrylic acid copolymer Eudragit® S100 (10% (w/v)) with the addition of the biopolymer sodium alginate, the composition of which was varied in the range (0.5% (w/v)-2% (w/v)). The microencapsulation process employed commercially available microfluidic droplet generation devices. We have used readily available low cost microfluidic chips instead of bespoke in-house fabricated glass capillary devices which are accessible only in specialist research facilities. We show that these co-flow microfluidic devices can easily be used to prepare phage encapsulated microparticles making them suitable for use by both the phage research community and industry in order to evaluate and optimise phage compatible formulations for microencapsulation. A novelty of the work reported here is that the size of the generated monodispersed droplets could be precisely controlled in the range 50 μm-200 μm by varying the flow rates of the dispersed and continuous phases. Consequently, alginate concentration and microparticle size were shown to influence the phage release profile and the degree of acid protection afforded to phages upon exposure to simulated gastric fluid (SGF). Bigger microparticles (∼100 μm) showed better acid protection compared with smaller beads (∼50 μm) made from the same formulation. Increasing the alginate composition resulted in improved acid protection of phages for similar particle sizes. The high viscosity formulations containing higher amounts of alginate (e.g. 2% (w/v)) negatively affected ease of droplet generation in the microfluidic device thereby posing a limitation in terms of process scale-up. Felix O1 encapsulated in the formulation containing 10% (w/v) ES100 and 1% (w/v) alginate showed excellent protection upon exposure of the gelled microparticles to SGF (pH 1 for 2 h) without the use of any antacids in the encapsulation matrix. Encapsulated phages previously exposed to SGF (pH 1 for 2 h) were released at elevated pH in simulated intestinal fluid (SIF) and were shown to arrest bacterial growth in the log growth phase. We have therefore demonstrated the microencapsulation of phages using readily available microfluidic chips to produce solid dosage microcapsule forms with a rapid pH triggered release profile suitable for targeted delivery and controlled release in the gastrointestinal tract.
一种沙门氏菌特异性噬菌体Felix O1(肌尾噬菌体科)被微囊化在一种pH响应性聚合物制剂中。该制剂包含一种pH响应性甲基丙烯酸共聚物Eudragit® S100(10%(w/v)),并添加了生物聚合物海藻酸钠,其组成在0.5%(w/v)-2%(w/v)范围内变化。微囊化过程采用了市售的微流控液滴生成装置。我们使用了现成的低成本微流控芯片,而不是只有在专业研究设施中才能获得的定制内部制造的玻璃毛细管装置。我们表明,这些共流微流控装置可轻松用于制备噬菌体包封的微粒,使其适合噬菌体研究界和工业界使用,以评估和优化用于微囊化的噬菌体兼容制剂。本文报道工作的一个新颖之处在于,通过改变分散相和连续相的流速,可以将生成的单分散液滴的尺寸精确控制在50μm-200μm范围内。因此,海藻酸钠浓度和微粒尺寸被证明会影响噬菌体的释放曲线以及在暴露于模拟胃液(SGF)时给予噬菌体的酸保护程度。与由相同制剂制成的较小珠子(约50μm)相比,较大的微粒(约100μm)显示出更好的酸保护。对于相似的粒径,增加海藻酸钠组成会导致噬菌体的酸保护得到改善。含有较高量海藻酸钠(例如2%(w/v))的高粘度制剂对微流控装置中液滴生成的便利性产生负面影响,从而在工艺放大方面构成限制。封装在含有10%(w/v)ES100和1%(w/v)海藻酸钠的制剂中的Felix O1,在凝胶化微粒暴露于SGF(pH 1,2小时)时表现出优异的保护作用,在封装基质中无需使用任何抗酸剂。先前暴露于SGF(pH 1,2小时)的封装噬菌体在模拟肠液(SIF)中在较高pH下释放,并被证明能在对数生长期阻止细菌生长。因此,我们证明了使用现成的微流控芯片对噬菌体进行微囊化,以生产具有快速pH触发释放曲线的固体剂型微胶囊,适用于胃肠道中的靶向递送和控释。